According to a new report, published by KBV research, The Global Live Biotherapeutic Products And Microbiome CDMO Market size is expected to reach $159.1 million by 2029, rising at a market growth of 42.5% CAGR during the forecast period.
The IBS market has shown the high growth rate of 44.6% during (2023 - 2029). The stomach and intestines, collectively known as the gastrointestinal system, are affected by the disorder known as irritable bowel syndrome (IBS). Constipation, diarrhea, bloating, gas, and cramps are a few of the symptoms. IBS needs to be managed as a chronic condition over the long term. Gut transit time, stool consistency, and overall stool frequency have all been proven to improve with the use of probiotics. As a result, more developments are taking place in the generation of LBPs for treating IBS, which is responsible for the expansion of the segment.
The North America market dominated the Global Live Biotherapeutic Products And Microbiome CDMO Market by Region in 2022, thereby achieving a market value of $111.8 million by 2029. The Europe market is poised to grow at a CAGR of 43.1% during (2023 - 2029). Additionally, The Asia Pacific market would witness a CAGR of 45.5% during (2023 - 2029).
Full Report: https://www.kbvresearch.com/live-biotherapeutic-products-and-microbiome-cdmo-market/
The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the globe with country wise analysis in each discussed region. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of Arranta Bio Holdings, LLC (Recipharm AB) (EQT AB), Cerbios-Pharma SA, Biose Industrie, List Biological Laboratories, Inc., AcuraBio Pty Ltd (Ampersand Capital Partners), Wacker Chemie AG (Dr. Alexander Wacker Familiengesellschaft mbH), Quay Pharmaceuticals Ltd (SGS S.A.), BiomX, Inc., Lonza Group AG, and 4D Pharma Plc.
By Application
By Geography
Companies Profiled
Unique Offerings 
